Biosimilar Newsletter Archive

  1. 09.21.23 -- De-Risking Biosimilar Development With A Clinically Validated And Commercially Proven Disposable Autoinjector 9/21/2023
    09/21/23 Biosimilar Development Newsletter
  2. 09.14.23 -- Biosimilars Forum Statement On CMS Announcement Of Drug Negotiation List 9/14/2023
    09/14/23 Biosimilar Development Newsletter
  3. 09.13.23 -- Affinity Chromatography For mAbs, Mechanistic Modeling, And Polishing 9/13/2023
    09/13/23 Biosimilar Development Newsletter
  4. 09.07.23 -- FDA Approves First Biosimilar To Treat MS 9/7/2023
    09/07/23 Biosimilar Development Newsletter
  5. 08.31.23 -- The Cancer Drug Shortage: When Quality Fails 8/31/2023
    08/31/23 Biosimilar Development Newsletter
  6. 08.30.23 -- Futureproof The Design Of Your Biomanufacturing Capacity 8/30/2023

    08/30/23 Biosimilar Development Newsletter

  7. 08.24.23 -- Key Post-Pandemic Trends In Global FDA Facility Observations 8/24/2023
    08/24/23 Biosimilar Development Newsletter
  8. 08.23.23 -- Mitigating Particulate Risk For Your Injectable Drug Product 8/23/2023

    08/23/23 Biosimilar Development Newsletter

  9. 08.17.23 -- 4 Key Considerations for Onshoring or Nearshoring Drug Production 8/17/2023
    08/17/23 Biosimilar Development Newsletter
  10. 08.10.23 -- Biomanufacturing Process Optimization And Scaling 8/10/2023

    08/10/23 Biosimilar Development Newsletter